Racial differences of lipoprotein subclass distributions in postmenopausal women

Ethnicity and Disease

Volumn 18, Issue 2, 2008, Pages 176-180

  Vora, Amit N ^a   Ouyang, Pamela ^a   Bittner, Vera ^b   Tardif, Jean Claude ^d   Waters, David D ^c   Vaidya, Dhananjay ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Lipoprotein Subclass Distributions; Postmenopausal Period; Race Differences

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASCORBIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

AFRICAN AMERICAN; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSTMENOPAUSE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; VITAMIN SUPPLEMENTATION; ADULT; ATHEROSCLEROSIS; BLOOD; CHEMISTRY; CLASSIFICATION; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL; WOMEN'S HEALTH;

ADULT; ATHEROSCLEROSIS; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PARTICLE SIZE; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; WOMEN'S HEALTH;

EID: 47749127380     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hopkins GJ, Barter PJ. Role of triglyceride- rich lipoproteins and hepatic lipase in determining the particle size and composition of high density lipoproteins.J Lipid Res. 1986; 27(12):1265-1277.
2. Alabakovska SB, Labudovic DD, Tosheska KN, Todorova BB. Low density lipoprotein particle size phenotyping in healthy persons and patients with myocardial infarction. Croatian Med J. 2002;4(3):290-295.
3. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low- density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988; 260(13):1917-1921.
4. Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA. 1994;272(4):305-308.
5. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary arrery disease regression. Hepatic lipase-mediated changes in LDL density. Circulation. 1999;99(15):1959- 1964.
6. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94(4): 350-356.
7. Ambrosch A, Muhlen I, Kopf D, et al. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and
8. healthy subjects. Diabetes Care. 1998;21(12): 2077-2084.
9. Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metab Clin Exp. 2005;54(2): 227-234.
10. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vase Biol. 002;22(7): 1175-1180.
11. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic tesonance spectroscopy to coronary artery disease. Arterioscler Thromb Vase Biol. 1998; 18(7): 1046-1053.
12. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotri- glyceridemic patients. Arterioscler Thromb. 1991;11(1):174-182.
13. Brown SA, Hutchinson R, Morrisett J, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993;13(8): 1139-1158.
14. Despres J-P, Couillard C, Gagnon J, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the health, risk factors, exercise training, and genetics (HERITAGE) family study. Arterioscler Thromb Vase Biol. 2000;20(8):1932-1938.
15. Morrison JA, Khoury P, Mellies M. Lipid and lipoprotein distributions in Black adults. The Cincinnati Lipid Research Clinic's Princeton School Study. JAMA. 1981;245(9):939-942.
16. Tyroler HA, Hames CG, Krishan I. Black- White differences in serum lipids and lipoproteins in Evans County. Prev Med. 1975;4, (4) 541-549.
17. Freedman DS, Bowman BA, Otvos JD, Srinivasan SR, Berenson GS. Levels and correlates of LDL and VLDL particle sizes among children: The Bogalusa Heart Study. Atherosclerosis. 2000;152(2):44l-449.
18. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294, (14) 1773-1781.
19. Johnson JL, Slentz CA, Duscha BD, et al. Gender and racial differences in lipoprotein subclass distributions: the STRR1DE study. Atherosclerosis. 2004;176(2):371-377.
20. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled rrial. JAMA. 2002; 288(19):2432-2440.
21. Hsia J, Alderman EL, Verier JI, et al. Women's angiographic vitamin and estrogen trial: design and ethods. Controlled Clinical Trials. 2002;23(6):708-727.
22. Lounila J, Ala-Korpela M, Jokisaari J, Savo- lainen MJ, Kesaniemi YA. Effects of orienta- tional order and particle size on the NMR line positions of lipoproteins. Phys Rev Lett. 1994;72(25):4049-4052.
23. Otvos J, Jeyarajah E, Bennett D. A spectroscopic approach to lipoprotein subclass analysis.J Clin Ligand Assay. 1996; 19:184-189.
24. Otvos JD, Jeyarajah EJ, Bennett DW. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem. 1991;37(3):377-386.
25. Otvos JD, Jeyarajah EJ, Bennett E>W, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992; 38(9):1632-1638.
26. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002; 106( 15): 1930-1937.
27. Thorn T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113(6) e85-151.
28. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966;34(4):679-697.
29. Ballantyne FC, Clark RS, Simpson HS, Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metab Clin Exp. 1982;31 (5):433-437.